Literature DB >> 25267081

A reduction in both visceral and subcutaneous fats contributes to increased adiponectin by lifestyle intervention in the Diabetes Prevention Program.

Chao Zhang1, Hao Luo, Feng Gao, Chun-Ting Zhang, Ren Zhang.   

Abstract

AIMS: Adiponectin, an insulin-sensitizing adipokine, confers protection against type 2 diabetes. Although adiponectin is secreted exclusively from fat, contributions of visceral adipose tissue (VAT) versus subcutaneous adipose tissue (SAT) to adiponectin levels have not been fully understood. We aimed to examine correlations between changes in VAT and SAT volumes and changes in adiponectin levels.
METHODS: Here, we have investigated the correlations between ΔVAT and ΔSAT with Δadiponectin in participants of the Diabetes Prevention Program, a clinical trial investigating the effects of lifestyle changes and metformin versus placebo on the rate of developing type 2 diabetes. Data on VAT and SAT volumes, measured by computed tomography, and on adiponectin levels at both baseline and 1-year follow-up were available in 321 men and 626 women.
RESULTS: In men, Δadiponectin was highly significantly correlated with both ΔSAT (r s  = -0.329) and ΔVAT (r s  = -0.413). Likewise, in women, Δadiponectin was correlated with both ΔSAT (r s  = -0.294) and ΔVAT (r s  = -0.348). In the lifestyle arm, Δadiponectin remained highly significantly correlated with ΔSAT and ΔVAT in men (r s  = -0.399 and r s  = -0.460, respectively), and in women (r s  = -0.372 and r s  = -0.396, respectively), with P < 0.001 for all above correlations.
CONCLUSIONS: We conclude that for both men and women, adiponectin changes are highly significantly correlated with changes in both SAT and VAT and that exercise- and weight-loss-induced reduction in both SAT and VAT contributes to the increased adiponectin.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25267081     DOI: 10.1007/s00592-014-0655-2

Source DB:  PubMed          Journal:  Acta Diabetol        ISSN: 0940-5429            Impact factor:   4.280


  9 in total

1.  Systemic arteriosclerosis and eating behavior in Japanese type 2 diabetic patients with visceral fat accumulation.

Authors:  Shiro Fukuda; Ayumu Hirata; Hitoshi Nishizawa; Hirofumi Nagao; Susumu Kashine; Takekazu Kimura; Kana Inoue; Yuya Fujishima; Masaya Yamaoka; Junji Kozawa; Tetsuhiro Kitamura; Tetsuyuki Yasuda; Norikazu Maeda; Akihisa Imagawa; Tohru Funahashi; Iichiro Shimomura
Journal:  Cardiovasc Diabetol       Date:  2015-01-16       Impact factor: 9.951

2.  Association of adiponectin gene polymorphism with adiponectin levels and risk for insulin resistance syndrome.

Authors:  Jai Prakash; Balraj Mittal; Shally Awasthi; Neena Srivastava
Journal:  Int J Prev Med       Date:  2015-04-08

3.  Benefits of Regular Exercise on Inflammatory and Cardiovascular Risk Markers in Normal Weight, Overweight and Obese Adults.

Authors:  Olivia Santos Gondim; Vinicius Tadeu Nunes de Camargo; Fernanda Almeida Gutierrez; Patricia Fátima de Oliveira Martins; Maria Elizabeth Pereira Passos; Cesar Miguel Momesso; Vinicius Coneglian Santos; Renata Gorjão; Tania Cristina Pithon-Curi; Maria Fernanda Cury-Boaventura
Journal:  PLoS One       Date:  2015-10-16       Impact factor: 3.240

4.  The effect of dapagliflozin treatment on epicardial adipose tissue volume.

Authors:  Takao Sato; Yoshifusa Aizawa; Sho Yuasa; Shohei Kishi; Koichi Fuse; Satoshi Fujita; Yoshio Ikeda; Hitoshi Kitazawa; Minoru Takahashi; Masahito Sato; Masaaki Okabe
Journal:  Cardiovasc Diabetol       Date:  2018-01-04       Impact factor: 9.951

5.  Longitudinal Increases in Adiposity Contribute to Worsening Adipokine Profile over Time in Mexican Americans.

Authors:  Mary Helen Black; Yu-Hsiang Shu; Jun Wu; Corinna Koebnick; Adrienne MacKay; Richard M Watanabe; Thomas A Buchanan; Anny H Xiang
Journal:  Obesity (Silver Spring)       Date:  2018-02-10       Impact factor: 5.002

6.  Effects of Exenatide and Humalog Mix25 on Fat Distribution, Insulin Sensitivity, and β-Cell Function in Normal BMI Patients with Type 2 Diabetes and Visceral Adiposity.

Authors:  Xinlei Wang; Xiaoqin Zhao; Yunjuan Gu; Xiaohui Zhu; Tong Yin; Zhuqi Tang; Jin Yuan; Wei Chen; Rong OuYang; Lili Yao; Rongping Zhang; Jie Yuan; Ranran Zhou; Yi Sun; Shiwei Cui
Journal:  J Diabetes Res       Date:  2020-05-26       Impact factor: 4.011

7.  Abdominal Adipose Tissue Associates With Adiponectin and TNFα in Middle-Aged Healthy Men.

Authors:  Hani Zaidi; Tonje Aksnes; Sissel Åkra; Heidi B Eggesbø; Rune Byrkjeland; Ingebjørg Seljeflot; Trine B Opstad
Journal:  Front Endocrinol (Lausanne)       Date:  2022-07-07       Impact factor: 6.055

8.  Changes in Levels of Biomarkers Associated with Adipocyte Function and Insulin and Glucagon Kinetics During Treatment with Dapagliflozin Among Obese Type 2 Diabetes Mellitus Patients.

Authors:  Aki Okamoto; Hirohide Yokokawa; Hironobu Sanada; Toshio Naito
Journal:  Drugs R D       Date:  2016-09

9.  The SGLT2 Inhibitor Dapagliflozin Significantly Improves the Peripheral Microvascular Endothelial Function in Patients with Uncontrolled Type 2 Diabetes Mellitus.

Authors:  Seigo Sugiyama; Hideaki Jinnouchi; Noboru Kurinami; Kunio Hieshima; Akira Yoshida; Katsunori Jinnouchi; Hiroyuki Nishimura; Tomoko Suzuki; Fumio Miyamoto; Keizo Kajiwara; Tomio Jinnouchi
Journal:  Intern Med       Date:  2018-03-30       Impact factor: 1.271

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.